Berkeley Lights Announces Appointment of Dr. Siddhartha Kadia to the Board of Directors
September 09 2021 - 5:00AM
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell
biology, today announced that Siddhartha Kadia, Ph.D. joined the
Berkeley Lights Board of Directors as an independent director,
effective September 7, 2021.
“I am excited to join the Berkeley Lights Board
of Directors," said Dr. Kadia. "I am passionate about technologies
that can transform the life science industry and the Berkeley
Lights platform is incredibly powerful, with value across a wide
range of applications and markets. I look forward to helping the
company deliver on its long-term strategies.”
"Siddhartha brings to Berkeley Lights extensive
global leadership experience, both as a CEO and as a public company
director, and I am very pleased to welcome him to our Board,” said
Eric Hobbs, Ph.D., chief executive officer of Berkeley Lights.
“Siddhartha will be a tremendous complement to the Board as it
helps guide our transformation of the biology market, while
delivering value to our shareholders.”
About Siddhartha Kadia
Dr. Kadia was president and CEO of EAG
Laboratories, a global scientific services company providing
analytical testing and consulting solutions, which was acquired by
Eurofins Scientific in December 2017. He continued to serve as the
CEO of EAG laboratories until December 2018. Prior to EAG
Laboratories, Dr. Kadia served in several senior roles including
the president of Life Sciences Division at Life Technologies
Corporation at the time of its acquisition by ThermoFisher
Scientific in February 2014. Prior to Life Technologies, Dr. Kadia
was a management consultant at McKinsey & Company in the
healthcare practice, assisting global medical device companies, and
major healthcare providers.
Dr. Kadia earned a B.E. in electronics and
telecommunications from Gujarat University in India, an M.S. in
biomedical engineering from Rutgers University, and a Ph.D. in
biomedical engineering from Johns Hopkins University. He is
currently a board member of ALS Limited (ASX:ALQ), Applied
Technical Services (ATS), BioSkryb Genomics, Isoplexis Corporation
and NuVasive (NSDQ:NUVA). Dr. Kadia’s experience also includes
prior public company board service as a director of Volcano
Corporation, Newport Corporation, and Horizon Discovery Group
plc.(LSE: HZD). In addition to corporate boards, Dr. Kadia serves
on the advisory boards of various academic institutions, including
Scripps Research Institute.
About Berkeley Lights
Berkeley Lights is a leading digital cell
biology company focused on enabling and accelerating the rapid
development and commercialization of biotherapeutics and other
cell-based products for our customers. The Berkeley Lights Platform
captures deep phenotypic, functional and genotypic information for
thousands of single cells in parallel and can also deliver the live
biology customers desire in the form of the best cells. Our
platform is a fully integrated, end-to-end solution, comprising
proprietary consumables, including our OptoSelect™ chips and
reagent kits, advanced automation systems, and application
software. We developed the Berkeley Lights Platform to provide the
most advanced environment for rapid functional characterization of
single cells at scale, the goal of which is to establish an
industry standard for our customers throughout their cell-based
product value chain.
Forward Looking Statement
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Berkeley Lights or its products, they are forward-looking
statements reflecting the current beliefs and expectations of
management. Such forward-looking statements involve substantial
known and unknown risks and uncertainties that relate to future
events, and actual results and product performance could differ
significantly from those expressed or implied by the
forward-looking statements. Berkeley Lights undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties relating to
the Berkeley Lights platform and the company’s execution on its
growth strategy and expansion into additional markets, see the
statements in the "Risk Factors" sections, and elsewhere, in our
filings with the U.S. Securities and Exchange Commission.
The Berkeley Lights Platform and the Berkeley
Lights’ Beacon® and Lightning™ systems and Culture Station™
instrument are FOR RESEARCH USE ONLY. Not for use in
diagnostic procedures.
Press Contact
pr@berkeleylights.com
Investor Contact
ir@berkeleylights.com
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024